Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $32
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Gregory Renza maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $31 to $32.
Truist Securities analyst Gregory Renza maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $31 to $32.